Trials / Completed
CompletedNCT01018914
A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients
A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf® (Tacrolimus)/ Myfortic® and Advagraf® (Extended Release Tacrolimus) / Myfortic® in de Novo Liver Transplant Recipients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To compare the safety and efficacy of Prograf® with Myfortic® to Advagraf® extended release tacrolimus with Myfortic® in de novo liver transplant recipients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prograf | oral |
| DRUG | Advagraf | oral |
| DRUG | Myfortic | oral |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2009-11-25
- Last updated
- 2016-01-29
Locations
3 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01018914. Inclusion in this directory is not an endorsement.